HAC Pharma

Company snapshot

H.A.C. Pharma is a French independent pharmaceutical “Exploitant” company. Since 2007, H.A.C. Pharma is delivering mature and innovative high value drugs to patients through distribution, in-licensing and acquisition deals. H.A.C. Pharma has unique end-to-end capabilities to market high therapeutic value drugs on the French market, especially in pathologies with reduced alternatives for the patien

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for HAC Pharma. Not investment advice.

• What is HAC Pharma?

  H.A.C. Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Neurogenic Orthostatic Hypotension. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, a

• Is HAC Pharma publicly traded?

  HAC Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does HAC Pharma develop or market?

  We link 2 drug profile(s) where HAC Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/h-a-c-pharma#company-drugs.

• What are the latest developments for HAC Pharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does HAC Pharma focus on?

  HAC Pharma focuses on Neurogenic Orthostatic Hypotension based on our analysis of their pipeline programs and drug development activities.